Norman David Eansor - 16 Mar 2021 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Role
Director
Signature
/s/ Michael Loiacono, Attorney-in-Fact
Issuer symbol
MRKR
Transactions as of
16 Mar 2021
Net transactions value
+$249,988
Form type
4
Filing time
08 Jun 2023, 21:35:39 UTC
Next filing
10 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRKR Common Stock Purchase $249,988 +14,285 +588% $17.50 16,713 16 Mar 2021 Direct F1
transaction MRKR Common Stock Gift $0 -14,285 -85% $0.000000 2,428 25 Mar 2021 Direct F1, F2
transaction MRKR Common Stock Gift $0 +7,142 $0.000000 7,142 25 Mar 2021 By the John R. Eansor 2020 Exempt Trust F1, F2
transaction MRKR Common Stock Gift $0 +7,142 $0.000000 7,142 25 Mar 2021 By the Scott Eansor 2020 Exempt Trust F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRKR Stock Option (right to buy) Award $0 +8,000 $0.000000 8,000 06 Jun 2023 Common Stock 8,000 $1.72 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a 10-1 reverse stock split which became effective on January 16, 2023.
F2 The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust.
F3 This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date.